1. Canellos GP, Lister TA, Sklar JL, editors. The lymphomas. 2nd ed. Philadelphia: W.B. Saunders Company; 2006.
2. Primic Žakelj M, Bračko M, Hočevar M, Pompe-Kirn V, Strojan P, Zadnik V, et al., editors. Cancer incidence in Slovenia 2004. Ljubljana: Institute of Oncology, Cancer registry of Slovenia; 2007.
3. Molina A. A decade of rituximab: improving survival outcomes in Non-Hodgkin’s lymphoma. Annu Rev Med. 2008;59:237–50. doi: 10.1146/annurev.med.59.060906.220345 .
4. Lucas BJ, Horning SJ. Monoclonal antibodies have finally arrived. In: Cavalli F, Armitage JO, Longo DL, editors. Annual of lymphoid malignancies. London: Martin Dunitz Ltd; 2001. p. 153–67.
5. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin’s lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 2005;24:2121–43. doi: 10.1038/sj.onc.1208349 .